Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH- toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells

Cancer Research

Volumn 57, Issue 16, 1997, Pages 3494-3497

  Simard, Jacques ^a   Sanchez, Rocio ^a   Poirier, Donald ^a   Gauthier, Sylvain ^a   Singh, Shankar M ^a   Merand, Yves ^a   Belanger, Alain ^a   Labrie, Claude ^a   Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTIESTROGEN; DROLOXIFENE; ESTRADIOL; ESTROGEN; FULVESTRANT; HYDROXYTAMOXIFEN; RALOXIFENE; TOREMIFENE;

ARTICLE; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADENOCARCINOMA; ALKALINE PHOSPHATASE; BENZOPYRANS; ENDOMETRIAL NEOPLASMS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; NEOPLASM PROTEINS; PIPERIDINES; PROPIONATES; RALOXIFENE; TAMOXIFEN; TOREMIFENE; TUMOR CELLS, CULTURED;

EID: 0030860885     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Labrie, F. Intracrinology. Mol. Cell. Endocrinol., 78: C113-C118, 1991.
2. Labrie, C., Martel, C., Dufour, J. M., Lévesque, C., Mérand, Y., and Labrie, F. Novel compounds inhibit estrogen formation and action. Cancer Res., 52: 610-615, 1992.
3. Wakeling, A. E. The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res. Treat., 25: 1-9, 1993.
4. Jordan, V. C. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res. Treat., 31: 4837-4844, 1994.
5. Powles, T. J. Efficacy of tamoxifen as treatment of breast cancer. Semin. Oncol., 24(Suppl. 1): S1-48-S1-54, 1997.
6. Gottardis, M. M., Robinson, S. P., Satyaswaroop, P. G., and Jordan, V. C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res., 48: 812-815, 1988.
7. Poulin, R., Mérand, Y., Poirier, D., Lévesque, C., Dufour, J. M., and Labrie, F. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells. Breast Cancer Res. Treat., 14: 65-76, 1989.
8. Chalbos, D., Philips, A., Galtier, F., and Rochefort, H. Synthetic antiestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3′,5′-monophosphate in MCF7 cells. Endocrinology, 133: 571-576, 1993.
9. Gallo, M. A., and Kaufman, D. Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Semin. Oncol., 24(Suppl. 1): S1-71-S1-80, 1997.
10. Jordan, V. C., and Assikis, V. J. Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin. Cancer Res., 1: 467-472, 1995.
11. MacMahon, B. Overview of studies on endometrial cancer and other types of cancer in humans: perspective of an epidemiologist. Semin. Oncol., 24(Suppl. 1): S1-122-S1-139, 1997.
12. Carlson, R. W. Overview from a medical oncologist. Semin. Oncol., 24(Suppl. 1): S1-151-S1-157, 1997.
13. Nayfield, S. G., Karp, J. E., Ford, L. G., Dorr, F. A., and Kramer, B. S. Potential role of tamoxifen in prevention of breast cancer. Cancer (Phila.), 83: 1450-1459, 1991.
14. Loser, R., Seibel, K., Roos, W., and Eppenberger, U. In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen, and 4-hydroxytamoxifen, Eur. J. Cancer & Clin. Oncol., 21: 985-990, 1985.
15. Valavaara, R. Phase II trials with toremifene in advanced breast cancer: a review. Breast Cancer Res. Treat., 16(Suppl.): 531-535, 1990.
16. Wakeling, A. E., and Bowler, J. ICI 182,780, a new antiestrogen with chronical, potential. J. Steroid Biochem. Mol. Biol., 43: 173-177, 1992.
17. Jones, C. D., Jevnikar, M. G., Pike, A. J., Peters, M. K., Black, L. J., Thompson, A. R., Falcone, J. F., and Clemens, J. A. Antiestrogens, 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)e-thoxy]- phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem., 27: 1057-1066, 1984.
18. Yang, N. N., Venugopalan, M., Hardikar, S., and Glasebrook, A. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science (Washington DC), 273: 1222-1225, 1996.
19. 5 adrenal steroids. Endocrinology, 127: 2757-2762, 1990.
20. Nishida, M., Kasahara, K., Kaneko, M., and Iwasaki, H. Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Acta Obstet. Gynaecol. Jpn., 37: 1103-1111, 1985.
21. Rodbard, D. Apparent positive cooperative effect in cyclic AMP and corticosteroid production by isolated adrenal cells in response to ACTH analogs. Endocrinology, 94: 1427-1437, 1974.
22. Weaver, C. A., Springer, P. A., and Katzenellenbogen, B. S. Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2-chloramphenicol acetyltransferase fusion genes transfected into MCF-7 human breast cancer cells. Mol. Endocrinol., 2: 936-945, 1988.
23. Satyaswaroop, P. G., Zaino, R. J., and Mortel, R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res., 44: 4006-4010, 1984.
24. Clarke, C. L., and Satyaswaroop, P. G. Photoaffinity labeling of the progesterone receptor from human endometrial carcinoma. Cancer Res., 45: 5417-5420, 1985.
25. Anzai, Y., Holinka, C. F., Kuramoto, H., and Gurpide, E. Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Cancer Res., 49: 2362-2365, 1989.
26. Croxtall, J. D., Elder, M. G., and White, J. O. Hormonal control of proliferation in the Ishikawa endometrial adenocarcinoma cell line. J. Steroid Biochem., 35: 665-669, 1990.
27. Jamil, A., Croxtall, J. D., and White, J. O. The effect of antiestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa). J. Mol. Endocrinol., 6: 215-221, 1991.
28. Smith, D. C., Prentice, R., Thompson, D. J., and Herrmann, W. L. Association of exogenous estrogen and endometrial carcinoma. N. Engl. J. Med., 293: 1164-1167, 1975.
29. Ziehl, H. K., and Finkle, W. D. Increased risk of endometrial carcinoma among users of conjugated estrogens. N. Engl. J. Med., 293: 1167-1170, 1975.
30. Hoover, R., Fraumeni, J. F., Everson, R., and Myers, M. H. Cancer of the uterine corpus after hormonal treatment for breast cancer. Lancet, 1: 885-887, 1976.
31. Harper, M. J., and Walpole, A. L. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature (Lond.), 212: 87, 1966.
32. Harper, M. J., and Walpole, A, L. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J. Reprod. Fertil., 13: 101-119, 1967.
33. Darbre, P. D., Curtis, S., and King, R. J. Effects of estradiol and tamoxifen on human breast cancer cells in serum-free culture. Cancer Res., 44: 2790-2793, 1984.
34. Cormier, E. M., and Jordan, V. C. Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor. Eur. J. Cancer & Clin. Oncol., 25: 57-63, 1989.
35. Nomura, Y., Tashiro, H., and Hisamatsu, K, Differential effects of estrogen and antiestrogen on in vitro clonogenic growth of human breast cancers in soft agar. J. Nail. Cancer Inst., 82: 1146-1149, 1990.
36. Lien, E. A., Solheim, E., Lea, O. A., Lundgren, S., Kvinnsland, S., and Ueland, P. M. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res., 49: 2175-2183, 1989.
37. Gauthier, S., Caron, B., Cloutier, J., Dory, Y. L., Favre, A., Larouche, D., Mailhot, J., Ouellet, C., Schwerdtfeger, A., Leblanc, G., Martel, C., Simard, J., Mérand, Y., Bélanger, A., Labrie, C., and Labrie, F. (S)-(+)-[4-[7-(2.2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy]-phenyl]-2H-1-benzopyran-3-yl]phenyl]-2,2-dimethyl-propanoate (EM-800): a highly potent, specific and orally active non-steroidal antiestrogen. J. Med. Chem., in press.
38. Couillard, S., Labrie, C., Gauthier, S., Mérand, Y., and Labrie, F. Highly potent and pure antiestrogenic activity of a new antiestrogen on human ZR-75-1 breast tumors in nude mice. In: Proc. Endocrine Society Meeting, San Francisco, 1996, p. 604.
39. Simard, J., Labrie, C., Bélanger, A., Gauthier, S., Singh, S. M., Mérand, Y., and Labrie, F. Characterization of the effects of the novel nonsteroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int. J. Cancer, in press.
40. Martel, C., Gauthier, S., Mérand, Y., Li. S., Provencher, L., and Labrie, F. Comparison of the effects of the new antiestrogens EM-800 and ICI 182 780 on estrogen-sensitive parameters in the ovariectomized mouse. In: Proc. Endocrine Society Meeting, San Francisco, 1996, p. 151.